DermBiont, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.dermbiont.com
A Trial of Safety/Efficacy of Test Article in Patients With Interdigital T. Pedis
Phase 2
Terminated
- Conditions
- Interdigital Tinea Pedis
- Interventions
- Other: Placebo GelDrug: Cohort 1 J. Lividum
- First Posted Date
- 2020-03-19
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- DermBiont, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT04315051
- Locations
- 🇩🇴
Instituto Dermatologico y Cirugia de Piel, Santo Domingo, Dominican Republic
Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo
Phase 2
Terminated
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: J. lividum
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- DermBiont, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT04192513
- Locations
- 🇩🇴
Instituto Dermatologico y Cirugia de Piel, Santo Domingo, Dominican Republic
Open Label, Single-dose, Dose Escalating Evaluation of the Safety and Tolerability of DBI-001 in Patients With T. Pedis
Phase 2
Completed
- Conditions
- Tinea Pedis
- Interventions
- Drug: J. Lividum
- First Posted Date
- 2019-11-05
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- DermBiont, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT04152226
- Locations
- 🇩🇴
Instituto Dermatologico y Cirugia de Piel, Santo Domingo, Dominican Republic
© Copyright 2025. All Rights Reserved by MedPath